ZA200304303B - Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists. - Google Patents
Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists. Download PDFInfo
- Publication number
- ZA200304303B ZA200304303B ZA200304303A ZA200304303A ZA200304303B ZA 200304303 B ZA200304303 B ZA 200304303B ZA 200304303 A ZA200304303 A ZA 200304303A ZA 200304303 A ZA200304303 A ZA 200304303A ZA 200304303 B ZA200304303 B ZA 200304303B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- substituted
- alkyl
- occurrence
- independently selected
- Prior art date
Links
- 239000003420 antiserotonin agent Substances 0.000 title description 4
- 239000000952 serotonin receptor agonist Substances 0.000 title description 4
- CVSGFMWKZVZOJD-UHFFFAOYSA-N pyrazino[2,3-f]quinoxaline Chemical class C1=CN=C2C3=NC=CN=C3C=CC2=N1 CVSGFMWKZVZOJD-UHFFFAOYSA-N 0.000 title description 2
- -1 ethylenedioxy Chemical group 0.000 claims description 250
- 125000000217 alkyl group Chemical group 0.000 claims description 204
- 125000003342 alkenyl group Chemical group 0.000 claims description 130
- 125000000304 alkynyl group Chemical group 0.000 claims description 119
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 95
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 85
- 125000003118 aryl group Chemical group 0.000 claims description 79
- 125000005842 heteroatom Chemical group 0.000 claims description 79
- 229910052757 nitrogen Inorganic materials 0.000 claims description 79
- 125000001188 haloalkyl group Chemical group 0.000 claims description 77
- 125000005843 halogen group Chemical group 0.000 claims description 68
- 125000000623 heterocyclic group Chemical group 0.000 claims description 67
- 125000003545 alkoxy group Chemical group 0.000 claims description 66
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- 229910052717 sulfur Inorganic materials 0.000 claims description 53
- 229910052760 oxygen Inorganic materials 0.000 claims description 52
- 125000002837 carbocyclic group Chemical group 0.000 claims description 47
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 42
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 42
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 29
- 229910052731 fluorine Inorganic materials 0.000 claims description 26
- 229910052801 chlorine Inorganic materials 0.000 claims description 24
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 19
- 150000003839 salts Chemical group 0.000 claims description 15
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 101100478297 Arabidopsis thaliana SR45 gene Proteins 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 125000005002 aryl methyl group Chemical group 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 claims description 3
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims description 3
- 101100240519 Caenorhabditis elegans nhr-13 gene Proteins 0.000 claims description 3
- 102220480121 H/ACA ribonucleoprotein complex subunit DKC1_R10A_mutation Human genes 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 59
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 33
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 30
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 22
- 125000001153 fluoro group Chemical group F* 0.000 claims 21
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims 4
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 4
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- 235000010290 biphenyl Nutrition 0.000 claims 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 3
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 2
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 claims 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims 2
- 125000005916 2-methylpentyl group Chemical group 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 125000005917 3-methylpentyl group Chemical group 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 2
- 101150065749 Churc1 gene Proteins 0.000 claims 2
- 102100038239 Protein Churchill Human genes 0.000 claims 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 claims 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- RXBMEHOLQJITJI-LEOXJPRUSA-N (4s)-5-amino-4-[[(2s)-2-[[(2s)-2-[[(4-bromophenyl)-hydroxyphosphoryl]methyl]-3-(3-phenyl-1,2-oxazol-5-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N)CP(O)(=O)C=1C=CC(Br)=CC=1)C(ON=1)=CC=1C1=CC=CC=C1 RXBMEHOLQJITJI-LEOXJPRUSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- RMAINTGPKFNBDP-UHFFFAOYSA-N 2-methylphenol Chemical group [CH2]C1=CC=CC=C1O RMAINTGPKFNBDP-UHFFFAOYSA-N 0.000 claims 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 claims 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims 1
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004125 inden-2-yl group Chemical group [H]C1=C(*)C([H])([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000002485 serotonin 2C agonist Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 9
- 108091005479 5-HT2 receptors Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 2
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 2
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 2
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 101150104779 HTR2A gene Proteins 0.000 description 2
- 101150013372 Htr2c gene Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 description 1
- ZBZOBDKYIFMLHI-UHFFFAOYSA-N 5h-indolo[3,2-b][1,8]naphthyridine Chemical class C1=CC=C2CC3=NC4=CC=CC=C4C3=NC2=N1 ZBZOBDKYIFMLHI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 101150009274 nhr-1 gene Proteins 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200007101 rs34049451 Human genes 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000036263 tachygastria Effects 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25676500P | 2000-12-20 | 2000-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200304303B true ZA200304303B (en) | 2004-09-02 |
Family
ID=22973498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200304303A ZA200304303B (en) | 2000-12-20 | 2003-06-02 | Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6638934B2 (fr) |
| EP (1) | EP1345942B9 (fr) |
| JP (2) | JP4346307B2 (fr) |
| KR (1) | KR20030069192A (fr) |
| CN (1) | CN1505631A (fr) |
| AT (1) | ATE318819T1 (fr) |
| AU (1) | AU2002248216B2 (fr) |
| BG (1) | BG107864A (fr) |
| BR (1) | BR0116347A (fr) |
| CA (1) | CA2431970A1 (fr) |
| DE (1) | DE60117617T2 (fr) |
| EE (1) | EE200300301A (fr) |
| ES (1) | ES2260335T3 (fr) |
| HU (1) | HUP0303513A3 (fr) |
| IL (1) | IL156201A0 (fr) |
| IS (1) | IS6850A (fr) |
| MX (1) | MXPA03005437A (fr) |
| NO (1) | NO20032795L (fr) |
| PL (1) | PL366060A1 (fr) |
| RU (1) | RU2003121406A (fr) |
| SK (1) | SK7022003A3 (fr) |
| WO (1) | WO2002059127A2 (fr) |
| ZA (1) | ZA200304303B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2003121406A (ru) * | 2000-12-20 | 2004-12-27 | Бристол-Маерс Сквибб Фарма Компани (Us) | Производные замещенных пиразинохиноксалинов в качестве агонистов и антагонистов рецептора серотонина |
| US7244843B2 (en) | 2003-10-07 | 2007-07-17 | Bristol-Myers Squibb Company | Modulators of serotonin receptors |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| WO2006022420A1 (fr) | 2004-08-25 | 2006-03-02 | Takeda Pharmaceutical Company Limited | Agents préventifs/remèdes pour l’incontinence de stress et procédé de sélection de ceux-ci |
| EP2742936A1 (fr) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique condensé et son utilisation |
| EP2216023A4 (fr) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | Dérivé de pyridine condensé et son utilisation |
| US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
| WO2012030953A1 (fr) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur 5-ht2c dans traitement de troubles améliorés par réduction du taux de noradrénaline |
| EP3610890A1 (fr) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Procédés et compositions de traitement de la schizophrénie |
| WO2015066344A1 (fr) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation |
| JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4013652A (en) | 1972-06-19 | 1977-03-22 | Endo Laboratories, Inc. | Pyridopyrrolobenzoxazine |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| HUT61548A (en) | 1990-08-27 | 1993-01-28 | Sandoz Ag | Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds |
| EP1140940A1 (fr) * | 1998-12-17 | 2001-10-10 | American Home Products Corporation | Derives de 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one utilises en tant qu'agonistes de 5ht2c |
| RU2003121406A (ru) * | 2000-12-20 | 2004-12-27 | Бристол-Маерс Сквибб Фарма Компани (Us) | Производные замещенных пиразинохиноксалинов в качестве агонистов и антагонистов рецептора серотонина |
-
2001
- 2001-12-19 RU RU2003121406/04A patent/RU2003121406A/ru not_active Application Discontinuation
- 2001-12-19 PL PL01366060A patent/PL366060A1/xx not_active Application Discontinuation
- 2001-12-19 EP EP01997097A patent/EP1345942B9/fr not_active Expired - Lifetime
- 2001-12-19 IL IL15620101A patent/IL156201A0/xx unknown
- 2001-12-19 KR KR10-2003-7008273A patent/KR20030069192A/ko not_active Application Discontinuation
- 2001-12-19 BR BR0116347-7A patent/BR0116347A/pt not_active Application Discontinuation
- 2001-12-19 DE DE60117617T patent/DE60117617T2/de not_active Expired - Lifetime
- 2001-12-19 AT AT01997097T patent/ATE318819T1/de active
- 2001-12-19 WO PCT/US2001/049374 patent/WO2002059127A2/fr active IP Right Grant
- 2001-12-19 ES ES01997097T patent/ES2260335T3/es not_active Expired - Lifetime
- 2001-12-19 SK SK702-2003A patent/SK7022003A3/sk unknown
- 2001-12-19 JP JP2002559429A patent/JP4346307B2/ja not_active Expired - Fee Related
- 2001-12-19 HU HU0303513A patent/HUP0303513A3/hu not_active Application Discontinuation
- 2001-12-19 EE EEP200300301A patent/EE200300301A/xx unknown
- 2001-12-19 AU AU2002248216A patent/AU2002248216B2/en not_active Ceased
- 2001-12-19 CN CNA01822704XA patent/CN1505631A/zh active Pending
- 2001-12-19 CA CA002431970A patent/CA2431970A1/fr not_active Abandoned
- 2001-12-19 US US10/026,404 patent/US6638934B2/en not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005437A patent/MXPA03005437A/es unknown
-
2003
- 2003-05-30 BG BG107864A patent/BG107864A/bg unknown
- 2003-06-02 ZA ZA200304303A patent/ZA200304303B/en unknown
- 2003-06-18 IS IS6850A patent/IS6850A/is unknown
- 2003-06-19 NO NO20032795A patent/NO20032795L/no not_active Application Discontinuation
-
2009
- 2009-05-11 JP JP2009114360A patent/JP5117440B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1345942B1 (fr) | 2006-03-01 |
| WO2002059127A2 (fr) | 2002-08-01 |
| WO2002059127A3 (fr) | 2002-10-03 |
| PL366060A1 (en) | 2005-01-24 |
| JP2004524298A (ja) | 2004-08-12 |
| EP1345942A2 (fr) | 2003-09-24 |
| US6638934B2 (en) | 2003-10-28 |
| DE60117617D1 (de) | 2006-04-27 |
| IS6850A (is) | 2003-06-18 |
| CA2431970A1 (fr) | 2002-08-01 |
| NO20032795D0 (no) | 2003-06-19 |
| JP5117440B2 (ja) | 2013-01-16 |
| US20020177596A1 (en) | 2002-11-28 |
| DE60117617T2 (de) | 2007-01-25 |
| BR0116347A (pt) | 2004-07-06 |
| IL156201A0 (en) | 2003-12-23 |
| ES2260335T3 (es) | 2006-11-01 |
| KR20030069192A (ko) | 2003-08-25 |
| EE200300301A (et) | 2003-10-15 |
| MXPA03005437A (es) | 2003-09-10 |
| JP2009215304A (ja) | 2009-09-24 |
| RU2003121406A (ru) | 2004-12-27 |
| HUP0303513A3 (en) | 2005-12-28 |
| EP1345942B9 (fr) | 2006-11-15 |
| NO20032795L (no) | 2003-08-04 |
| SK7022003A3 (en) | 2004-08-03 |
| HUP0303513A2 (hu) | 2004-01-28 |
| ATE318819T1 (de) | 2006-03-15 |
| BG107864A (bg) | 2004-03-31 |
| CN1505631A (zh) | 2004-06-16 |
| AU2002248216B2 (en) | 2007-03-01 |
| JP4346307B2 (ja) | 2009-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200304304B (en) | Substituted pyrroloquinolines and pyridoquinolines as serotomin agonists and antagonists. | |
| ZA200304305B (en) | Sustituted tetracyclic pyridoindoles as serotonin agonists and antagonists. | |
| US5597826A (en) | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | |
| US7081455B2 (en) | Substituted heterocycle fused gamma-carbolines | |
| US7183282B2 (en) | Substituted heterocycle fused γ-carbolines | |
| ZA200304303B (en) | Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists. | |
| JP2002523506A (ja) | 肥満の処置のためのピロロキノリン | |
| US6780862B2 (en) | Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands | |
| AU2002248216A1 (en) | Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists | |
| US5714483A (en) | Antitussive | |
| PT85656B (pt) | Processos para a preparacao de 2,3,4,5,6,7-hexaidro-2,7-metano-1,5- benzoxazoninas e- 1,4- benzoxazoninas e de preparacoes farmaceuticas que as contem | |
| Howard et al. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | |
| AU2002246725A1 (en) | Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |